logo
Share SHARE
FONT-SIZE Plus   Neg

Appeals Court Says Rituxan, Avastin Do Not Infringe Sanofi Patents

An appeals court on Thursday upheld a lower court's ruling that the cancer drugs Rituxan and Avastin of Swiss drug maker Roche Holding AG's (RHHBY.PK) Genentech unit and biotechnology firm Biogen Idec Inc. (BIIB) do not infringe two patents of French drug maker Sanofi SA (SNY,SNYNF.PK).

Genentech's Avastin, which had sales of 5.29 billion Swiss francs in 2011, is a blockbuster drug for treatment of cancers related to colon, lung, kidney and brain. Rituxan had sales of 6.01 billion Swiss francs in 2011. Rituxan is currently co-marketed by Biogen Idec and Genentech in the U.S.

In a ruling posted on the court's website, the U.S. Court of Appeals for the Federal Circuit said that Sanofi's '522 and '140 patents were not infringed by Genentech and Biogen. The court ruled that the district court had not erred in its judgment.

In October 2008, Sanofi filed a lawsuit for infringement of the two patents, alleging that Genentech and Biogen made use of an infringing enhancer in producing the antibody-based drugs Rituxan and Avastin.

SNY closed Thursday's trading at $38.45, down $0.23 or 0.59 percent on a volume of 1.86 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Google Maps introduced a new feature to share real-time location to a contact for 15 minutes to 3 days. The feature can be turned off at any time by the user. The tech leader believes that the feature will help friends meet up in a large park or a restaurant at a new location. One can open share... Instagram is expected to announce Wednesday that it has one million monthly active advertisers, representing a five-fold increase from a year ago. The photo and video app, owned by Facebook, had 500,000 monthly active advertisers in September 2016 and just 200,000 active advertisers a year ago. Offensive and extremist content appearing along with display ads has been creating headache for Google. There has been strong protests and boycott of ads by major advertisers and this has forced the company to expand their controls. The tech giant said the advertisers will have more say to display...
comments powered by Disqus
Follow RTT